Brilinta Taiwan Post Approval Safety Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT02406248

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02406248
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02406248. Allocation not applicable; no masking; primary purpose treatment. Start 2015-04-23 (actual); primary completion 2017-02-09 (actual). Results posted on 2018-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Brilinta Taiwan Post Approval Safety Study
Condition
Non ST-elevation Myocardial Infarction
Intervention (Drug)
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02406248
Content hash
a3a07fb1a4aa5d4b32aa730a9a6ed7194055c6a2466995ac0ac02c17ed8c6d0c